Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Red~Oneon Mar 23, 2022 10:21am
282 Views
Post# 34537467

Quietly released

Quietly released

 

Claritas Pharmaceuticals private placement

 

2022-03-21 16:19 ET - Private Placement

 

The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement announced on Jan. 17, 2022, and updated on Jan. 26, 2022.

 

Number of shares:  1,081,081 shares

 

 

Purchase price:  13.875 cents per share

 

 

Warrants:  1,081,081 share purchase warrants to purchase 1,081,081 shares

 

 

Warrant exercise price:   Twenty-one cents for a three-year period. The warrants are subject to an acceleration clause such that if the 20-day volume weighted average closing price of company's common shares trading on the TSX Venture Exchange is equal or exceeds 42 cents. In the event of acceleration, the company will have the right, upon providing notice to the holder, to accelerate the warrant expiry date to the date which is not earlier than 30 days following the date of receipt of the notice from the company announcing the reduced warrant terms.

 

 

Number of placees:  one placee

 

 

Insiders/pro groups:   none

 

 

Finder's fee:  none

<< Previous
Bullboard Posts
Next >>